Clean enough for a dip? Paris set to reopen the Seine for swimming, but locals aren't so sure
Starting on 5 July, three public swimming sites will open along the Seine River - one near Notre Dame, another by the Eiffel Tower, and a third in eastern Paris.
The reopening is part of one of the French capital'ns most ambitious Olympic legacies. At a cost of around $1.5 billion (€1.27bn), the river has undergone a massive cleanup operation to transform it from a polluted, boat-choked artery into a swimmable urban oasis.
The sites will be free to use, supervised by lifeguards, and will operate on a daily schedule throughout the summer. A colour-coded flag system - green for safe, red for nope - will let visitors know whether it's swim time or sunbathe-only time.
But many Parisians remain hesitant on whether or not to take the plunge. The Seine's surface can still appear murky, litter floats by, and bacteria levels are known to fluctuate with the weather.
Dan Angelescu, a scientist and founder of Fluidion, has been independently testing the river's water quality for years. He warns that the current official testing methods may not accurately reflect the real-time risks: "What we see is that the water quality in the Seine is highly variable and it is, there are only a few days in a swimming season where I would say water quality is acceptable for swimming, according to the regulations currently in place."
"All we can say is that we can raise a hand and say look, the science today does not support the current assessment of water safety used in the in the rivers around Paris, and we think that there is major risk that is not being captured at all."
But with over 35 species of fish now calling the Seine home - compared to just a handful in the 1970s - it's clear the cleanup has had an impact. But whether Parisians will follow the fish into the water remains to be seen.
Check out the video above for more on the Seine swimming initiative.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
11 hours ago
- Medscape
10-Minute Test Exposes Antibiotic Resistance Threat
Current methods for assessing antibiotic resistance typically rely on bacterial cultures, a process that can take up to 2 days. Such delays can be critical in urgent clinical settings. To address this, researchers at France's National Institute for Research in Digital Science and Technology (Inria) are developing a rapid method that can deliver results within a few hours or even minutes. This new approach is based on the principle that antibiotic resistance results from mutations in the bacterial genome. In theory, sequencing can detect these changes; however, conventional sequencing methods are time-consuming. Karel Břinda, PhD, is a permanent Principal Investigator with the GenScale team at Inria Rennes, one of the regional research centers of Inria. He specializes in computational genomics and rapid diagnostic methods. The technique he developed compared bacterial DNA from patient samples with a reference database of genomes from bacteria known to be resistant or sensitive to antibiotics. Bacteria with similar DNA sequences are likely to exhibit similar resistance profiles. This method, known as Genomic Neighbor Typing, offers two key advantages: It does not require prior knowledge of the pathogen's complex biology, and it can generate predictions from minimal sequencing data, making it exceptionally fast. 'We've shown that once sequencing begins, we can predict resistance or susceptibility in about 10 minutes,' Břinda explained in an interview published by Inria. The technique uses a compact, portable nanopore sequencing device that is approximately the same size as a smartphone. 'With nanopores, you receive a continuous stream of data as soon as the device starts sequencing. Our method allows you to make a prediction almost immediately from this initial data, so the diagnosis is very fast,' he said. 'These devices also produce very long reads, which help identify the nearest genomic neighbors of the pathogen present in the patient's biological samples,' Břinda said. Although promising, this method has only been validated for Streptococcus pneumoniae and Neisseria gonorrhoeae . However, it is not yet applicable to all bacterial species or antibiotics, mainly because of gaps in existing genomic reference databases. To address this, Inria partnered with Rennes University Hospital, Rennes, France, to combine its computational tools with biological and clinical expertise. The hospital also houses a national collection of Enterococcus strains maintained by France's Reference Center for Antibiotic Resistance. 'In the long run, the key question revolves around building large and truly representative databases of bacterial strains,' said Břinda. 'Today, we work with databases of up to thousands of genomes. In the future, sequencing will become increasingly cheaper and more common. We will therefore have much larger databases. But we will then need new computational methods and new software.'
Yahoo
2 days ago
- Yahoo
Press Release: Sanofi's SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration
Sanofi's SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration Designation earned for a one-time intravitreal gene therapy designed to inhibit two key complement cascade pathways Geographic atrophy is an advanced form of dry age-related macular degeneration, that can lead to permanent vision loss Paris, July 16, 2025. The US Food and Drug Administration (FDA) has granted fast track designation to SAR446597, a one-time intravitreal gene therapy for the treatment of geographic atrophy (GA) due to age-related macular degeneration (AMD). The fast track designation process aims to facilitate the development and expedite the review of medicines to treat serious conditions and fill unmet medical need. The FDA created this process to help deliver important new drugs to patients earlier and it covers a broad range of serious illnesses. SAR446597 delivers genetic material encoding two therapeutic antibody fragments that target and inhibit two critical components of the complement pathway: C1s in the classical pathway and factor Bb in the alternative pathway. This dual-targeting approach potentially offers clinical advantages by providing sustained complement suppression within the retinal microenvironment while significantly reducing treatment burden through elimination of frequent intravitreal injections. The therapy aims to address the underlying pathophysiology of complement-mediated retinal diseases through long-term expression of therapeutic proteins following a single intervention. Sanofi plans to start a phase 1/2 study to evaluate the safety, tolerability, and efficacy of SAR446597. Sanofi is also currently evaluating SAR402663, a one-time intravitreal gene therapy, in a phase 1/2 study (clinical study identifier: NCT06660667), for the treatment of patients with neovascular wet age-related macular degeneration. About age-related macular degeneration and geographic atrophy AMD is an acquired progressive degeneration of the retina that affects approximately 200 million people globally. Geographic atrophy is an advanced form of dry AMD. It is characterized by enlarging irreversible atrophic lesions due to degeneration of retinal cells leading to permanent vision loss in many patients. GA affects approximately 1 million people in the US, more than 2.5 million in Europe, and over 5 million people worldwide and has a profound impact on quality of life, including ability to read, drive and perform other daily activities. About Sanofi in neurologyOur goal is to improve the lives of people with serious neuroinflammatory and neurodegenerative diseases. We are testing the bounds of clinical possibility to research therapies that may address multiple sclerosis (MS), chronic inflammatory demyelinating polyneuropathy (CIDP), Alzheimer's Disease (AD), Parkinson's disease (PD), Age-Related Macular Degeneration (AMD) and other neurological diseases for the people who need them most. Emerging scientific innovations and investments in ophthalmology have the potential to drive a new phase of growth for Sanofi. We are exploring innovative therapies in retinal diseases with unmet need especially where they connect with immune system conditions. About Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY Media RelationsSandrine Guendoul | +33 6 25 09 14 25 | Berland | +1 215 432 0234 | Léo Le Bourhis | +33 6 75 06 43 81 | Victor Rouault | +33 6 70 93 71 40 | Timothy Gilbert | +1 516 521 2929 | Ubaldi | +33 6 30 19 66 46 | Investor RelationsThomas Kudsk Larsen |+44 7545 513 693 | Alizé Kaisserian | +33 6 47 04 12 11 | Lauscher | +1 908 612 7239 | Browne | +1 781 249 1766 | Nathalie Pham | +33 7 85 93 30 17 | Elgoutni | +1 617 710 3587 | Thibaud Châtelet | +33 6 80 80 89 90 | Li | +33 6 84 00 90 72 | Sanofi forward-looking statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words 'expects', 'anticipates', 'believes', 'intends', 'estimates', 'plans' and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under 'Risk Factors' and 'Cautionary Statement Regarding Forward-Looking Statements' in Sanofi's annual report on Form 20-F for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. All trademarks mentioned in this press release are the property of the Sanofi Press Release
Yahoo
2 days ago
- Yahoo
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients- 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI- Topline results expected in the second half of 2026 LILLE, France & PARIS, July 16, 2025--(BUSINESS WIRE)--4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P004. "Enrolling our first patient is a pivotal step toward rewriting the treatment paradigm for knee osteoarthritis," said Professor Francis Berenbaum, MD, PhD, Chief Medical Officer at 4Moving Biotech. "Almost 600 million people live with OA, yet no disease-modifying therapy has been done to patients. By acting directly in the joint, 4P004 tackles pain, inflammation, and tissue damage through GLP-1-mediated pathways. We believe its targeted intra-articular delivery can unlock the full therapeutic power of GLP-1 biology. We are eager to confirm both symptomatic relief and meaningful structural benefit in this proof-of-concept study". The study's primary endpoint is the reduction in knee pain at week 4 and 12. Key secondary objectives include assessing synovial changes by contrast-enhanced MRI and conducting an exploratory analysis of blood and imaging biomarkers as potential surrogates for long-term disease progression and delay to total knee replacement. The study timeline covers 12 months, with patient enrollment taking place over 9 months and follow-up to be completed before the topline readout in the second half of 2026. INFLAM MOTION has been designed to generate the first human evidence that 4P004 can deliver both clinical relief and measurable structural benefit. Insights from this Phase 2a readout will shape the forthcoming Phase 2b program, whose primary aim will be to confirm surrogate endpoints that reliably predict the hard endpoint that is delaying the time to total knee replacement. About 4MBIncorporated in mid-2020 as a spin-off of 4P-Pharma, 4MB is a clinical stage biotechnology company dedicated to the development of the Disease-Modifying Osteoarthritis Drug (DMOAD). Its mission is to provide a sustainable therapeutic solution to the significant unmet medical need of osteoarthritis. The company is headquartered at the Pasteur Institute in Lille, LinkedIn: The only version of the 4Moving Biotech press release that is legally binding is the one in its original language. Translations must always be compared to the source text, which will establish precedence. The press release text resulting from a translation should not be considered official in any way. View source version on Contacts Press Emmanuel DadjéCommunication +33 6 30 06 12 13 Error in retrieving data Sign in to access your portfolio Error in retrieving data
